Bioorganic and Medicinal Chemistry Letters p. 2013 - 2018 (1999)
Update date:2022-09-26
Topics:
Buijsman, Rogier C.
Basten, Jan E. M.
Van Dinther, Theo G.
Van der Marel, Gijsbert A.
Van Boeckel, Constant A. A.
Van Boom, Jacques H.
The synthesis of a novel antithrombotic consisting of a heparin pentasaccharide conjugated to the active site inhibitor N-(2- naphtalenesulfonyl)-glycyl-(D)-4-aminophenyl-alanyl-piperidine (NAPAP) (i.e. compound I) is reported. This conjugate shows a unique pharmacological profile both in vitro and in vivo having direct anti-thrombin and ATIII- mediated anti-Xa activity. Furthermore, conjugate I has a prolonged in vivo half-life compared to NAPAP (1.5 h vs 9 min.).
View MoreContact:13120882795；+86-21-34621078;+86-021-31122318
Address:Suite 2,No.2715 Longwu Road
Geen Chemical Technology Co., Ltd
Contact:86-769-21660847
Address:1408, Yingfeng Commercial Center, Nancheng District
Qingdao Kingway Pharmtech Co., Ltd.
Contact:86-532-87118899
Address:No. 88, Middle Haixi Road, Jiaonan City, Qingdao, China
Shandong Hao Hong Biotechnology Co.,Ltd
Contact:0635-6175299
Address:No.5,North Guandao street, Gao Tang town, Shandong, China
Shanghai AoBo Bio-Pharmaceutical Technology Co., Ltd.
Contact:+86-21-51320130-801, 816
Address:Room 601, No. 1011, Halei Road, Zhangjiang High-Tech Park, Pudong, Shanghai
Doi:10.1021/ja00506a029
(1979)Doi:10.1016/S0040-4039(97)01496-2
(1997)Doi:10.1002/adsc.201900264
(2019)Doi:10.1021/ja01014a047
(1968)Doi:10.1055/s-1999-2902
(1999)Doi:10.1016/j.bmcl.2007.03.066
(2007)
